Plaintiff
1 case as plaintiff.
Cigna Corp. (The Cigna Group) — Legal name The Cigna Group (formerly Cigna Corporation); common short names "Cigna" and "The Cigna Group." Headquarters: 900 Cottage Grove Road, Bloomfield, Connecticut. Public, NYSE: CI (Delaware-incorporated holding company, incorporated 2018 per FT; the business traces to 1792 per Forbes/WSJ). Roughly 67,700–73,500 employees depending on source and reporting date; FY2025 total revenues of about $274.9 billion (company Q4 2025 earnings supplement). Chairman/CEO David M. Cordani.
Operations. Cigna is an operating company, not an NPE. It runs two segments: Evernorth Health Services (pharmacy benefit management, specialty pharmacy, home delivery pharmacy, specialty distribution, care delivery and management — the PBM business associated with Express Scripts) and Cigna Healthcare (U.S. medical plans and coordinated care, plus International Health supplemental health, life and accident products). "Other Operations" holds corporate-owned life insurance and run-off/non-strategic businesses.
Litigation posture. Across tracked cases, Cigna appears once as plaintiff and zero times as defendant. That profile is consistent with a large payer that litigates to recover drug costs rather than an entity asserting patents for licensing revenue; Cigna has no NPE/PAE characteristics. The tracked case sits in the U.S. District Court for the Eastern District of Pennsylvania — not a plaintiff-friendly patent venue such as the Eastern District of Texas — and is a competition/antitrust action, with patents as the alleged mechanism rather than as asserted claims.
Notable case and context. Cigna Corp. v. Celgene Corp. (E.D. Pa., No. 2:21-cv-00090, filed January 8, 2021) alleged that Celgene — acquired by Bristol-Myers Squibb in January 2019 — monopolized Thalomid and Revlimid by withholding samples from generic developers, inducing API-supplier exclusivity, fraudulently obtaining patents, filing baseless citizen petitions, and bringing "sham" patent suits, causing Cigna to overpay. The parties jointly moved to transfer venue, and the court granted transfer to the District of New Jersey (No. 2:21-cv-11686), consolidating with related insurer actions (Humana, UnitedHealthcare, BCBSM; In re Revlimid and Thalomid Purchaser Antitrust Litigation). Press reports (Benzinga/Bloomberg Law, June 2025) describe a further Cigna antitrust suit against BMS/Celgene over pomalidomide (Pomalyst), alleging similar conduct.
Later antitrust complaint referencing the Thalomid distribution-method patent family and mentioning the '018 patent within the family narrative. The narrative states the '018 patent was not asserted for infringement in this matter.